Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants.
VanRyzin, Jonathan W
Baglot, Samantha L
Hill, Matthew N
Clark, Sarah M
McCarthy, Margaret M
JournalPharmacology Research & Perspectives
PublisherBritish Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
MetadataShow full item record
AbstractModulation of the endocannabinoid system (ECS) is a novel putative target for therapeutic intervention in depressive disorders. Altering concentrations of one of the principal endocannabinoids, N-arachidonoylethanolamine, also known as anandamide (AEA) can affect depressive-like behaviors through several mechanisms including anti-inflammatory, hormonal, and neural circuit alterations. Recently, isoflavonoids, a class of plant-derived compounds, have been of therapeutic interest given their ability to modulate the metabolism of the endogenous ligands of the ECS. To determine the therapeutic potential of isoflavonoids, we screened several candidate compounds (Genistein, Biochanin-A, and 7-hydroxyflavone) in silico to determine their binding properties with fatty acid amide hydrolase (FAAH), the primary degrative enzyme for AEA. We further validated the ability of these compounds to inhibit FAAH and determined their effects on depressive-like and locomotor behaviors in the forced swim test (FST) and open field test in male and female mice. We found that while genistein was the most potent FAAH inhibitor, 7-hydroxyflavone was most effective at reducing immobility time in the forced swim test. Finally, we measured blood corticosterone and prefrontal cortex AEA concentrations following the forced swim test and found that all tested compounds decreased corticosterone and increased AEA, demonstrating that isoflavonoids are promising therapeutic targets as FAAH inhibitors.
Data AvailibilityThe authors confirm that the data that support the findings of this study are available within the article and its supplementary materials.
Rights/Terms© 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19643
- Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase.
- Authors: Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, Ross RA, Pertwee RG, Gereau RW 4th, Wiley JL, Fowler CJ
- Issue date: 2010 Jun
- Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats.
- Authors: Carnevali L, Statello R, Vacondio F, Ferlenghi F, Spadoni G, Rivara S, Mor M, Sgoifo A
- Issue date: 2020 Mar
- Role for fatty acid amide hydrolase (FAAH) in the leptin-mediated effects on feeding and energy balance.
- Authors: Balsevich G, Sticht M, Bowles NP, Singh A, Lee TTY, Li Z, Chelikani PK, Lee FS, Borgland SL, Hillard CJ, McEwen BS, Hill MN
- Issue date: 2018 Jul 17
- Upregulation of Anandamide Hydrolysis in the Basolateral Complex of Amygdala Reduces Fear Memory Expression and Indices of Stress and Anxiety.
- Authors: Morena M, Aukema RJ, Leitl KD, Rashid AJ, Vecchiarelli HA, Josselyn SA, Hill MN
- Issue date: 2019 Feb 13
- Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
- Authors: Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG
- Issue date: 2013 Jan